Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Type I Hereditary Angioedema (HAE), Type II Hereditary Angioedema (HAE), and Type III Hereditary Angioedema (HAE)), Drug Class (C-1 Esterase Inhibitors, Bradykynin B2 Receptor Antagonist, Kallikrein Inhibitors, Others), Application (Prophylaxis and Treatment), Route of Administration (Oral and Injectable), End User (Home Healthcare, Hospitals, Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031.
.
The Global Hereditary Angioedema Therapeutic Market size was valued at USD 3.91 USD Billion in 2023.
The Global Hereditary Angioedema Therapeutic Market is projected to grow at a CAGR of 8.72% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
